01—Abstract
Summary
Summary of the 10-Q filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation (BSX) reported strong financial results for the second quarter and first half of 2024, demonstrating robust top-line growth and improved profitability.
Net sales for the second quarter of 2024 reached $4.12 billiona, a 14.5% increase over the prior year, driven by broad-based performance across its segments, particularly Cardiology and MedSurg. For the first half of the year, net sales grew 14.1% to $7.98 billion. The company highlighted significant adoption of its Farapulse™ Pulsed Field Ablation System as a key growth driver.
Adjusted net income per diluted share for Q2 2024 was $0.62b, a substantial increase from $0.53 in the prior year, reflecting operational efficiencies and strong sales execution. The company also continues to strategically invest in its product pipeline and pursue significant acquisitions, including definitive agreements to acquire Axonics, Inc. and Silk Road Medical, Inc. These results underscore the company's ongoing commitment to innovation and market leadership in the medical device sector, positioning it for continued growth.
02—Key points
Key Highlights
- Net sales increased by 14.5% to $4.12 billion for the second quarter of 2024 compared to $3.599 billion in the prior year.
- First half net sales rose by 14.1% to $7.977 billion, up from $6.988 billion in the prior year.
- The Farapulse™ Pulsed Field Ablation System is a significant growth driver, with strong commercial adoption noted.
- Reported net income attributable to common stockholders was $324 million ($0.22 per diluted share) for Q2 2024, compared to $261 million ($0.18 per diluted share) in Q2 2023.
- Adjusted net income per diluted share for Q2 2024 was $0.62, an increase from $0.53 in Q2 2023.
- The company announced definitive agreements to acquire Axonics, Inc. for approximately $3.670 billion and Silk Road Medical, Inc. for approximately $1.260 billion, expected to close in the second half of 2024.
- Intangible asset impairment charges were $276 million in Q2 2024, primarily related to acquisitions of Cryterion Medical, Inc. and Devoro Medical, Inc.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Boston Scientific Corp kept $0.08.
- Revenue$4.12B100.0%
- Cost of revenue−$1.27B30.8%
- Gross profit$2.85B69.2%
- Operating costs−$2.33B56.6%
- Operating income$520.0M12.6%
- Interest, other & tax−$196.0M4.8%
- Net income$324.0M7.9%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $4.12B$3.60B | +14.5% |
| Cost of Revenue | $1.27B$1.06B | +20.0% |
| Gross Profit | $2.85B$2.54B | +12.1% |
| SG&A Expenses | $1.45B$1.35B | +6.8% |
| Operating Expenses | $2.33B$2.03B | +14.9% |
| Operating Income | $520.00M$514.00M | +1.2% |
| Interest Expense | $77.00M$70.00M | +10.0% |
| Net Income | $324.00M$270.00M | +20.0% |
| EPS (Basic) | $0.22$0.18 | +22.2% |
| EPS (Diluted) | $0.22$0.18 | +22.2% |
| Shares Outstanding (Basic) | 1.47B1.45B | +1.7% |
| Shares Outstanding (Diluted) | 1.48B1.46B | +1.9% |
05—Questions
Frequently Asked Questions
What were the main drivers of revenue growth in the second quarter of 2024?
Revenue growth in the second quarter of 2024 was primarily driven by strong commercial execution across Boston Scientific's businesses. Key contributors included the rapid adoption of its Farapulse™ Pulsed Field Ablation System, along with continued growth in its electrophysiology business, Left Atrial Appendage Closure (LAAC) procedures with WATCHMAN devices, access solutions, and percutaneous coronary intervention guidance franchises.
What is the status of the planned acquisitions of Axonics and Silk Road Medical?
Boston Scientific has announced definitive agreements to acquire both Axonics, Inc. for approximately $3.670 billion and Silk Road Medical, Inc. for approximately $1.260 billion. Both transactions are expected to close in the second half of 2024, subject to customary closing conditions. The Axonics acquisition is undergoing review by the FTC, which has issued a Second Request for information.
How did the company's profitability change in the second quarter of 2024?
The company showed improved profitability in the second quarter of 2024. Reported net income attributable to common stockholders increased to $324 million ($0.22 per diluted share) from $261 million ($0.18 per diluted share) in the prior year. More significantly, adjusted net income per diluted share increased to $0.62 from $0.53 in the prior year, reflecting strong sales and operational efficiencies, despite notable intangible asset impairment charges.
Are there any significant non-recurring charges impacting the financial results?
Yes, Boston Scientific recorded intangible asset impairment charges of $276 million in the second quarter of 2024. These charges are primarily related to amortizable intangible assets from prior acquisitions of Cryterion Medical, Inc. and Devoro Medical, Inc., due to factors like strong commercial adoption of newer technologies impacting older ones, or program cancellations.
06—Continue